Cyclerion Therapeutics, Inc. (CYCN)

Sorry, no known transcripts

Recent filings

Departure of Directors or Certain - Sept. 30, 2022

Cyclerion Therapeutics Announces Positive Topline Clinical Data For Cy6463 In - July 28, 2022

Cyclerion Therapeutics, Inc. insider was just granted 57,753 options - July 27, 2022

Steven E. Hyman, M.D., Appointed To Cyclerion Therapeutics’ Board Of Directors - July 26, 2022

Cyclerion Therapeutics, Inc. insider just declared owning 0 shares of Cyclerion Therapeutics, Inc. - July 26, 2022

Cyclerion Therapeutics, Inc. insider was just granted 57,753 options - July 26, 2022

Cyclerion Therapeutics, Inc. insider was just granted 20,000 options - June 16, 2022

Cyclerion Therapeutics, Inc. insider was just granted 20,000 options - June 16, 2022

Cyclerion Therapeutics, Inc. insider was just granted 20,000 options - June 16, 2022

Cyclerion Therapeutics, Inc. insider was just granted 20,000 options - June 16, 2022

Cyclerion Therapeutics, Inc. insider was just granted 20,000 options - June 16, 2022

Cyclerion Therapeutics, Inc. insider was just granted 20,000 options - June 16, 2022

Cyclerion Therapeutics, Inc. insider was just granted 20,000 options - June 16, 2022

Submission of Matters to a Vote of Security - June 15, 2022

Cyclerion Therapeutics Announces Positive Topline Clinical Data For Cy6463 In Melas Patients At Umdf Mitochondrial Medicine 2022 Symposium - June 10, 2022

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - June 3, 2022

Cyclerion Therapeutics, Inc. Just Filed Its Quarterly Report: 9. Loss per shareBas... - May 4, 2022

Cyclerion Therapeutics: Cyclerion Announces Cy6463 Clinical Pipeline Progress And First Quarter 2022 Financial Results - May 4, 2022

Cyclerion Therapeutics: Soliciting Material Pursuant To §240.14A-12 Cyclerion Therapeutics, Inc. - April 26, 2022

Other definitive proxy statements - April 26, 2022

Mr. Amaury Wittouck just provided an update on share ownership of Cyclerion Therapeutics, Inc. - Feb. 11, 2022

Slate Path Capital LP just provided an update on share ownership of Cyclerion Therapeutics, Inc. - Feb. 11, 2022

Statement of acquisition of beneficial ownership by individuals - Feb. 9, 2022

Statement of acquisition of beneficial ownership by individuals - Feb. 9, 2022

Cyclerion Therapeutics, Inc. insider was just granted 135,000 options - Jan. 24, 2022

Cyclerion Therapeutics, Inc. insider was just granted 482,950 options - Jan. 24, 2022

Cyclerion Therapeutics, Inc. insider was just granted 135,000 options - Jan. 24, 2022

Cyclerion Therapeutics, Inc. insider was just granted 135,000 options - Jan. 24, 2022

Cyclerion Therapeutics, Inc. insider was just granted 100,000 options - Dec. 10, 2021

Cyclerion Therapeutics, Inc. insider was just granted 100,000 options - Dec. 10, 2021

Cyclerion Therapeutics, Inc. insider was just granted 75,000 options - Dec. 10, 2021

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results And Corporate Update - Nov. 9, 2021

Cyclerion Therapeutics, Inc. Just Filed Its Quarterly Report: 10. Loss per shareBa... - Nov. 9, 2021

Departure of Directors or Certain - Oct. 28, 2021

Current report, items 7.01 and 9.01 - Sept. 30, 2021

Quarterly report [Sections 13 or 15(d)] - Aug. 27, 2021

Annual report [Section 13 and 15(d), not S-K Item 405] - Aug. 27, 2021

Quarterly report [Sections 13 or 15(d)] - Aug. 27, 2021

Departure of Directors or Certain - Aug. 19, 2021

Securities to be offered to employees in employee benefit plans - July 30, 2021

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results And Corporate Update - July 29, 2021

Cyclerion Therapeutics, Inc. Just Filed Its Quarterly Report: 10. Loss per share B... - July 29, 2021

Statement of changes in beneficial ownership of securities - June 28, 2021

Statement of changes in beneficial ownership of securities - June 28, 2021

Cyclerion Therapeutics, Inc. insider was just granted 10,000 options - June 28, 2021

Cyclerion Therapeutics, Inc. insider was just granted 10,000 options - June 28, 2021

Cyclerion Therapeutics, Inc. insider was just granted 10,000 options - June 28, 2021

Statement of changes in beneficial ownership of securities - June 28, 2021

Cyclerion Therapeutics, Inc. insider was just granted 10,000 options - June 28, 2021

Statement of changes in beneficial ownership of securities - June 28, 2021

Current report, item 5.07 - June 25, 2021

Prospectus [Rule 424(b)(4)] - June 24, 2021

Notice of Effectiveness - June 23, 2021

Registration statement under Securities Act of 1933 - June 23, 2021

Notice of Exempt Offering of Securities, item 06b - June 17, 2021

Registration statement under Securities Act of 1933 - June 16, 2021

Cyclerion Therapeutics, Inc. director just picked up 96,153 shares - June 7, 2021

Major owner of Cyclerion Therapeutics, Inc. just picked up 961,538 shares - June 7, 2021

General statement of acquisition of beneficial ownership - June 7, 2021

Cyclerion Therapeutics, Inc. insider just picked up 823,170 shares - June 7, 2021

Cyclerion Therapeutics Announces Global Licensing Agreement With Akebia Therapeutics For Praliciguat - June 4, 2021

Initial statement of beneficial ownership of securities - May 19, 2021

General statement of acquisition of beneficial ownership - May 14, 2021

Cyclerion Therapeutics, Inc. insider just picked up 302,000 shares - May 10, 2021

Cyclerion Therapeutics, Inc. insider just picked up 698,001 shares - May 6, 2021

Current report, items 1.02 and 9.01 - May 4, 2021

Cyclerion Therapeutics, Inc. Just Filed Its Quarterly Report: 10. Loss per share B... - April 30, 2021

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - April 28, 2021

Other definitive proxy statements - April 28, 2021

Current report, items 2.02, 7.01, and 9.01 - April 27, 2021

Current report, items 5.02, 7.01, and 9.01 - April 26, 2021

Cyclerion Therapeutics Announces Departure Of Chief Medical Officer - March 19, 2021

Cyclerion Therapeutics Announces Departure Of Chief Medical Officer - March 18, 2021

Cyclerion Therapeutics, Inc. insider just disposed of 1,824 shares - March 1, 2021

Cyclerion Therapeutics, Inc. insider just disposed of 2,637 shares - March 1, 2021

Annual report [Section 13 and 15(d), not S-K Item 405] - Feb. 25, 2021

Michael F. DeMichele just provided an update on share ownership of Cyclerion Therapeutics, Inc. - Feb. 12, 2021

Statement of acquisition of beneficial ownership by individuals - Feb. 8, 2021

American Endowment Foundation just provided an update on share ownership of Cyclerion Therapeutics, Inc. - Feb. 5, 2021

Current report, items 2.02, 7.01, and 9.01 - Jan. 13, 2021

Cyclerion Therapeutics, Inc. insider just declared owning 9,294 shares of Cyclerion Therapeutics, Inc. - Jan. 11, 2021

Cyclerion Therapeutics, Inc. insider just declared owning 33,423 shares of Cyclerion Therapeutics, Inc. - Jan. 11, 2021

Cyclerion Therapeutics, Inc. insider just declared owning 45,365 shares of Cyclerion Therapeutics, Inc. - Dec. 30, 2020

Cyclerion Therapeutics, Inc. insider just disposed of 20,107 shares - Dec. 30, 2020

Departure of Directors or Certain - Dec. 21, 2020

Sorry, no schedule available for this company

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates - Feb. 24, 2022

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration - Feb. 23, 2022

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference - Nov. 11, 2021

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator - Sept. 22, 2021

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit - Aug. 23, 2021

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update - July 29, 2021

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC) - July 22, 2021

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership - July 8, 2021

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat - June 4, 2021

Cyclerion Therapeutics Announces $18 Million Private Placement - June 4, 2021

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology - May 27, 2021

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference - May 25, 2021

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress - April 27, 2021

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors - April 26, 2021

Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference - April 21, 2021

Cyclerion Therapeutics to Host Pipeline Update Webinar - April 20, 2021

Cyclerion Therapeutics Announces Departure of Chief Medical Officer - March 18, 2021

Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards - Jan. 25, 2021

Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference - Jan. 4, 2021

Cyclerion Announces Leadership Transitions - Dec. 21, 2020

 


Feedback